Abstract
Inhaled corticosteroids (ICS) are the cornerstone of asthma management both in adults and in children. There are some adverse effects related to the use of these drugs in all ages. Those adverse effects can be local or systemic. From the paediatric point of view, the main worry relates to the effect on growth and on the integrity of the HPA-axis. At the recommended doses, their effect on the latter is not clinically relevant and the slight modification of cortisol levels which occurs while taking them reflects their presence in blood. Although there is a slowing down on growth velocity, this is reduced to the first months of treatment which are followed by a catch up: there is quite consistent data supporting their lack of significant effect on the final height. Other adverse effects which may appear in relation to ICS treatment in children, including infants, are mild or very sporadic. However, it is important to bear in mind that a small proportion of asthmatic children may have a certain idiosyncrasy which makes them especially sensitive to ICS. Furthermore, a close follow up is warranted when, due to the disease severity, higher than the recommended doses of ICS are administered.
Keywords: Adverse effects, asthma, inhaled corticosteroids, safety
Current Drug Safety
Title: Inhaled Corticosteroids in Asthmatic Children: Are They as Safe in Infants and Preschoolers as in Older Children? A Review
Volume: 3 Issue: 1
Author(s): Luis Garcia-Marcos, Jose A. Ros-Lucas and Manuel Sanchez-Solis
Affiliation:
Keywords: Adverse effects, asthma, inhaled corticosteroids, safety
Abstract: Inhaled corticosteroids (ICS) are the cornerstone of asthma management both in adults and in children. There are some adverse effects related to the use of these drugs in all ages. Those adverse effects can be local or systemic. From the paediatric point of view, the main worry relates to the effect on growth and on the integrity of the HPA-axis. At the recommended doses, their effect on the latter is not clinically relevant and the slight modification of cortisol levels which occurs while taking them reflects their presence in blood. Although there is a slowing down on growth velocity, this is reduced to the first months of treatment which are followed by a catch up: there is quite consistent data supporting their lack of significant effect on the final height. Other adverse effects which may appear in relation to ICS treatment in children, including infants, are mild or very sporadic. However, it is important to bear in mind that a small proportion of asthmatic children may have a certain idiosyncrasy which makes them especially sensitive to ICS. Furthermore, a close follow up is warranted when, due to the disease severity, higher than the recommended doses of ICS are administered.
Export Options
About this article
Cite this article as:
Garcia-Marcos Luis, Ros-Lucas A. Jose and Sanchez-Solis Manuel, Inhaled Corticosteroids in Asthmatic Children: Are They as Safe in Infants and Preschoolers as in Older Children? A Review, Current Drug Safety 2008; 3 (1) . https://dx.doi.org/10.2174/157488608783334005
DOI https://dx.doi.org/10.2174/157488608783334005 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fractions of <i>Boswellia Serrata</i> Suppress LTA<sub>4</sub>, LTC<sub>4</sub>, Cyclooxygenase-2 Activities and mRNA in HL-60 Cells and Reduce Lung Inflammation in BALB/c Mice
Current Drug Discovery Technologies Rational Pharmacotherapy and Pharmacovigilance
Current Drug Safety Exosomal MicroRNA: Diagnostic Marker and Therapeutic Tool for Lung Diseases
Current Pharmaceutical Design Molecular and Biotechnological Advances in Milk Proteins in Relation to Human Health
Current Protein & Peptide Science Trisodium Citrate Dihydrate-Catalyzed One-Pot Three-component Synthesis of Biologically Relevant Diversely Substituted 2-Amino-3-Cyano-4-(3- Indolyl)-4H-Chromenes under Eco-Friendly Conditions
Current Green Chemistry New Methods of Prevention and Treatment of Allergic Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Genetic Insights into Sepsis: What have we Learned and How will it Help?
Current Pharmaceutical Design The Use of Methotrexate in Respiratory Diseases
Current Respiratory Medicine Reviews Endogenous Glutathione Adducts
Current Drug Metabolism An Overview of Non-Neural Sources of Calcitonin Gene-Related Peptide
Current Medicinal Chemistry Biologically Active Peptides Interacting with the G Protein-Coupled Formylpeptide Receptors
Protein & Peptide Letters Cosignaling Molecules Around LIGHT-HVEM-BTLA: From Immune Activation to Therapeutic Targeting
Current Molecular Medicine Subject Index To Volume 7
Current Drug Metabolism Evaluation of the <i>In Vivo</i> Acute Toxicity and <i>In Vitro</i> Hemolytic and Immunomodulatory Activities of the <i>Moringa oleifera</i> Flower Trypsin Inhibitor (MoFTI)
Protein & Peptide Letters Molecular Mechanisms and Treatment of Radiation-Induced Lung Fibrosis
Current Drug Targets Editorial (Thematic Issue: Natural Products for the Attenuation of Allergic Airway Inflammation)
Current Pharmaceutical Design Inhibitors of Phosphoinositol 3 Kinase and NFκB for the Treatment of Chronic Obstructive Pulmonary Disease
Recent Patents on Inflammation & Allergy Drug Discovery Myalgic Encephalomyelitis: Symptoms and Biomarkers
Current Neuropharmacology Natural Naphthoquinones with Great Importance in Medicinal Chemistry
Current Organic Synthesis Advancement in Nanoparticle-based Biosensors for Point-of-care <i>In vitro</i> Diagnostics
Current Topics in Medicinal Chemistry